Decoy Therapeutics (NASDAQ:DCOY) Stock Short Interest Jumps 1,321.2%

Decoy Therapeutics (NASDAQ:DCOY) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 150,336 shares, a growth of 1,321.2% from the September 15th total of 10,578 shares. Based on an average trading volume of 11,986,981 shares, the short-interest ratio is presently 0.0 days. Currently, 23.3% of the company’s shares are sold short.

Decoy Therapeutics Stock Down 3.3%

DCOY stock opened at $1.47 on Friday. The company has a market cap of $970,200.00, a price-to-earnings ratio of -0.05 and a beta of 0.65. Decoy Therapeutics has a twelve month low of $1.46 and a twelve month high of $55.92. The business has a 50 day moving average price of $2.94 and a two-hundred day moving average price of $4.99.

Decoy Therapeutics (NASDAQ:DCOY) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($4.46) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million during the quarter. On average, equities research analysts anticipate that Decoy Therapeutics will post -8.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Decoy Therapeutics in a research report on Wednesday, September 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $30.00.

Decoy Therapeutics Company Profile

Decoy Therapeutics, Inc is a biotechnology company focused on discovering and developing antiviral medicines. The company’s research is based on the use of engineered “decoy” molecules designed to interfere with interactions between viruses and human cells, with the goal of preventing viral infection or limiting disease progression.

Decoy Therapeutics is developing a pipeline of investigational therapies intended to address viral diseases. Its platform is focused on creating treatments that may have activity against multiple viral strains or variants, although specific products, development stages and commercialization plans may change as the company advances its research programs.

Publicly available information about Decoy Therapeutics’ leadership, operating geographies and corporate history is limited.